The company posted Rs 134 crore in the same quarter last year.
The company’s revenue from operations rose to Rs 963 crore in Q3 FY25, a 14%Y-o-Y rise from Rs 845 crore reported in Q3FY24.
Operating EBITDA grew by 15% to Rs 270 crores, while EBITDA margins rose 30 basis points YoY to 28.1%.
JB Pharma’s domestic business grew by 22% YoY to Rs 566 crore, driven by strong demand for products such as Cilacar, Cilacar-T, Rantac, Nicardia, Metrogyl, and Sporlac.
Domestic business now constitutes 59% of overall turnover in nine months of FY25.JB Pharma outperformed IPM and clocked YoY growth of 12% versus IPM (Indian pharmaceutical market) growth of 8% as per IQVIA MAT December 2024 data.As per IQVIA MAT Dec’24 data, its Razel franchise acquired from Glenmark recorded YoY growth of 26% to INR 97 croresInternational business revenue grew by 4% at Rs 397 crores
“Our India business continues to drive market beating growth led by chronic business and progressive portfolio within the acute segment,” said Nikhil Chopra, CEO and Wholetime Director, JB Pharma
“Our export business continues to be steady with sequential improvement witnessed in our CDMO business, while the growth run-rate of JB’s quarterly performance has been maintained, we have also improved our operating margins driven by product mix and efficiency initiatives,” he added.
